OncoMatch/Clinical Trials/NCT06213311
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Is NCT06213311 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Glofitamab and Obinutuzumab for b cell lymphoma.
Treatment: Glofitamab · Obinutuzumab · Axi-cel — To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
Histologically proven CD19- and CD20-positive LBCL
Required: CD20 overexpression (positive)
Histologically proven CD19- and CD20-positive LBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody — first-line
Participants must have received first-line therapy including: Anti-CD20 monoclonal antibody
Must have received: anthracycline — first-line
Participants must have received first-line therapy including: An anthracycline containing chemotherapy regimen
Cannot have received: CAR T-cell therapy
Prior CAR T-cell therapy
Cannot have received: glofitamab (glofitamab)
Prior...glofitamab therapy
Cannot have received: systemic immunotherapeutic agents (radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, monoclonal antibodies (e.g., anti-CTLA4, anti-PD1 and anti-PDL1))
Prior treatment with systemic immunotherapeutic agents, including but not limited to radio-immunoconjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (e.g., anti-CTLA4, anti-PD1 and anti-PDL1) within 4 weeks or five half-lives of the drug, whichever is shorter, before Gpt infusion.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1000/μL; Platelet count either ≥ 75,000/μL or >50K if documented lymphomatous involvement of bone marrow; Absolute lymphocyte count ≥ 100/μL
Kidney function
Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 ml/min
Liver function
Serum alanine aminotransferase and aspartate aminotransferase ≤ 2.5 upper limit of normal (ULN); Total bilirubin ≤ 1.5 mg/dL, except in participants with Gilbert's syndrome
Cardiac function
Cardiac ejection fraction ≥ 45%, no evidence of pericardial effusion (except trace or physiological) as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings
Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as: Absolute neutrophil count ≥ 1000/μL; Platelet count either ≥ 75,000/μL or >50K if documented lymphomatous involvement of bone marrow; Absolute lymphocyte count ≥ 100/μL; Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 ml/min; Serum alanine aminotransferase and aspartate aminotransferase ≤ 2.5 upper limit of normal (ULN); Total bilirubin ≤ 1.5 mg/dL, except in participants with Gilbert's syndrome; Cardiac ejection fraction ≥ 45%, no evidence of pericardial effusion (except trace or physiological) as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings; No clinically significant pleural effusion; Baseline oxygen saturation > 92% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify